18742746. ORAL CODELIVERY OF NAVITOCLAX AND Bcl2 siRNA TREATING GASTIC CANCER (Board of Regents, The University of Texas System)

From WikiPatents
Revision as of 07:42, 19 December 2024 by Wikipatents (talk | contribs) (Creating a new page)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

ORAL CODELIVERY OF NAVITOCLAX AND Bcl2 siRNA TREATING GASTIC CANCER

Organization Name

Board of Regents, The University of Texas System

Inventor(s)

Md Nurunnabi of El Paso TX (US)

Humayra Afrin of El Paso TX (US)

Raj Kumar of El Paso TX (US)

ORAL CODELIVERY OF NAVITOCLAX AND Bcl2 siRNA TREATING GASTIC CANCER

This abstract first appeared for US patent application 18742746 titled 'ORAL CODELIVERY OF NAVITOCLAX AND Bcl2 siRNA TREATING GASTIC CANCER



Original Abstract Submitted

Compositions and methods are described for oral treatment of gastric cancer. A composition of matter for treatment of gastric cancer includes navitoclax; and Bcl2 siRNA. The composition can include β-glucan and docosahexaenoic acid as a mucoadhesive nanocarrier.

Retrieved from "http://wikipatents.org/index.php?title=18742746._ORAL_CODELIVERY_OF_NAVITOCLAX_AND_Bcl2_siRNA_TREATING_GASTIC_CANCER_(Board_of_Regents,_The_University_of_Texas_System)&oldid=271755"